| Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. | |
| | |
MedLine Citation:
|
PMID: 17306703 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein (ESP), improves exercise capacity in patients with symptomatic chronic heart failure (CHF) and anemia. BACKGROUND: Anemia is common in patients with CHF. METHODS: In a multicenter, randomized, double-blind, placebo-controlled study, CHF patients with anemia (hemoglobin > or =9.0 to < or =12.0 g/dl) received subcutaneous placebo (n = 22) or darbepoetin alfa (n = 19) at a starting dose of 0.75 microg/kg every 2 weeks for 26 weeks. The primary end point was change in exercise tolerance from baseline to week 27 as measured by peak oxygen uptake (ml/min/kg body weight). Other end points included changes in absolute peak VO2 (ml/min), exercise duration, and health-related quality of life. RESULTS: Differences (95% confidence interval) in mean changes from baseline to week 27 between treatment groups were 1.5 g/dl (0.5 to 2.4) for hemoglobin concentration (p = 0.005), 0.5 ml/kg/min (-0.7 to 1.7) for peak VO2 (p = 0.40), 45 ml/min (-35 to 127) for absolute peak VO2 (p = 0.27), and 108 s (-11 to 228) for exercise duration (p = 0.075). Patients receiving darbepoetin alfa compared with placebo had an improvement in self-reported Patient's Global Assessment of Change (79% vs. 41%, p = 0.01) but no significant differences in the Kansas City Cardiomyopathy and Minnesota Living with Heart Failure Questionnaire scores. Darbepoetin alfa was well tolerated. CONCLUSIONS: In patients with symptomatic CHF and anemia, darbepoetin alfa increased and maintained hemoglobin concentrations and improved health-related quality of life. A trend toward increased exercise time but not peak VO2 was observed. (Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia; http://clinicaltrials.gov/ct/show/NCT00117234?order = 1; NCT00117234). |
| | |
Authors:
|
Piotr Ponikowski; Stefan D Anker; Joanna Szachniewicz; Darlington Okonko; Mark Ledwidge; Robert Zymlinski; Enda Ryan; Scott M Wasserman; Nigel Baker; Dylan Rosser; Stuart D Rosen; Philip A Poole-Wilson; Waldemar Banasiak; Andrew J S Coats; Ken McDonald |
Related Documents
:
|
15187823 - Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure ... 8813833 - Alterations of breathing in chronic heart failure: clinical relevance of arterial oxyge... 21563023 - Cardiovascular responses during hypoventilation at exercise. |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2007-02-05 |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 49 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-02-19 Completed Date: 2007-03-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 753-62 Citation Subset: AIM; IM |
Affiliation:
|
Cardiac Department, Military Hospital, Wroclaw, Poland. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00117234 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Activities of Daily Living Aged Anemia / etiology*, physiopathology*, therapy Body Weight Double-Blind Method Erythropoietin / analogs & derivatives*, therapeutic use Exercise Test / drug effects Exercise Tolerance / drug effects* Female Heart Failure / complications* Hematinics / therapeutic use* Hemoglobins / drug effects Hospitalization Humans Injections, Subcutaneous Male Natriuretic Peptide, Brain / blood Oxygen Consumption / drug effects Quality of Life Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hematinics; 0/Hemoglobins; 11096-26-7/Erythropoietin; 114471-18-0/Natriuretic Peptide, Brain; 209810-58-2/darbepoetin alfa |
| Comments/Corrections | |
Comment In:
|
J Am Coll Cardiol. 2007 Feb 20;49(7):763-4
[PMID:
17306704
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endothelial progenitor cells in cardiovascular disorders.
Next Document: Feasibility of endovascular recanalization for symptomatic cervical internal carotid artery occlusio...